<DOC>
	<DOCNO>NCT02724566</DOCNO>
	<brief_summary>Preclinical study demonstrate mouse model ( PYR1 ) -apelin-13 exert glucose-regulating action vivo . The ( PYR1 ) -apelin-13 effect insulin sensitivity healthy overweighed volunteer previously assess phase I clinical trial ( APELINS study ; NCT02033473 ) . The APELINS-2 clinical trial aim expand initial proof concept population target future innovative insulin-sensitizing therapy : patient live type 2 diabetes .</brief_summary>
	<brief_title>Effect Apelin Insulin Sensitivity Type 2 Diabetic Volunteers</brief_title>
	<detailed_description>Insulin sensitivity measure use hyperinsulinemic euglycemic glucose clamp method . The hypothesis investigator continuous ( pyr1 ) -apelin-13 infusion improve insulin sensitivity type 2 diabetic patient compare placebo infusion . This study could bring new element understand pathophysiology insulin resistance type 2 diabetes mellitus human could lead development innovative therapy type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Clinical diagnosis type2 diabetes Body Mass Index 27 33 kg / cm Â² HbA1c &lt; 8.5 % Nonpathological Electrocardiogram Heart rate 50 80 beat per minute rest . Complete Blood Count ( CBC ) significant anomaly term investigator.. Serum electrolytes without clinically significant abnormality term investigator . Liver function test without clinically significant abnormality term investigator Renal function test without clinically significant abnormality term investigator Good peripheral vein ( forearm back hand ) . Agreement participate establishment serum bank . Ability sign inform consent . Affiliation social security scheme Secondary prevention cardiovascular disease Insulin therapy Glucagon Like Peptid 1 ( GLP1 ) analogs therapy 6 month inclusion . Risk factor , treatment electrocardiogram recommend International Conference Harmonization ( ICH ) E14 `` Clinical Evaluation QT / QTc Interval Prolongation Proarrhythmic Potential NonAntiarrhythmic Drugs '' Repeated QTc interval &gt; 450 m measurement Risk factor torsade de pointes : myocardial infarction , hypokalemia , family history long QT syndrome Personal history cancer . Positive HIV serology . Hepatitis B serology positive . Positive hepatitis C serology . Cognitive impairment mental illness ( discretion investigator ) . Chronic excessive alcohol consumption ( consumption &gt; 30g/day 210g/week ) . Person judicial protection , guardianship . Subject rest systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mmHg Smoking 10 cigaret per day interrupt 24 hour .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Type 2 diabetic volunteer</keyword>
</DOC>